ETNB 89Bio

89bio to Participate in Upcoming Investor Conferences

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May:

BofA Securities 2025 Health Care Conference

Format: Fireside Chat

Date: Wednesday, May 14, 2025

Time: 1:40 PM ET

2025 RBC Capital Markets Global Healthcare Conference

Format: Fireside Chat

Date: Tuesday, May 20, 2025

Time: 9:30 AM ET

The webcast of the fireside chats will be accessible in the investor section of . A replay of the webcasts will be available for approximately 30 days following each conference.

About 89bio

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on

Investor Contact: 

Annie Chang 

89bio, Inc.

PJ Kelleher

LifeSci Advisors, LLC

617-430-7579

Media Contact:

Sheryl Seapy

Real Chemistry



EN
06/05/2025

Underlying

ETNB89Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 89Bio

 PRESS RELEASE
Free
ETNB 89BIO

89bio to Participate in Upcoming Investor Conferences

89bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May: BofA Securities 2025 Health Care ConferenceFormat: Fireside ChatDate: Wednesday, May 14, 2025Time: 1:40 PM ET 2025 RBC Capital Markets Gl...

8h / 39m 1 EN
 PRESS RELEASE
Free
ETNB 89BIO

89bio Reports First Quarter 2025 Financial Results and Corporate Updat...

89bio Reports First Quarter 2025 Financial Results and Corporate Updates – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; completed...

May 1, 2025 1 EN
 PRESS RELEASE
Free
ETNB 89BIO

89bio to Participate in the Leerink Partners Global Healthcare Confere...

89bio to Participate in the Leerink Partners Global Healthcare Conference SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of th...

March 3, 2025 1 EN
 PRESS RELEASE
Free
ETNB 89BIO

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and ...

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expec...

February 27, 2025 1 EN
 PRESS RELEASE
Free
ETNB 89BIO

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company’s common stock to seven new employees (the “Inducement ...

February 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch